AlphaCrest Capital Management’s Telus TU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-28,315
Closed -$562K 1066
2022
Q3
$562K Sell
28,315
-129,495
-82% -$2.89M 0.03% 930
2022
Q2
$3.52M Buy
157,810
+30,968
+24% +$766K 0.17% 128
2022
Q1
$3.32M Buy
126,842
+26,236
+26% +$648K 0.19% 105
2021
Q4
$2.37M Buy
100,606
+39,458
+65% +$902K 0.09% 338
2021
Q3
$1.34M Buy
61,148
+5,368
+10% +$121K 0.07% 484
2021
Q2
$1.25M Sell
55,780
-120,468
-68% -$2.61M 0.05% 549
2021
Q1
$3.51M Buy
176,248
+88,744
+101% +$1.84M 0.2% 119
2020
Q4
$1.73M Sell
87,504
-6,660
-7% -$125K 0.14% 176
2020
Q3
$1.66M Buy
94,164
+59,878
+175% +$1.06M 0.18% 124
2020
Q2
$575K Buy
34,286
+24,054
+235% +$400K 0.1% 333
2020
Q1
$161K Sell
10,232
-82,426
-89% -$1.53M 0.02% 964
2019
Q4
$1.79M Sell
92,658
-77,834
-46% -$1.44M 0.15% 138
2019
Q3
$3.04M Buy
170,492
+33,046
+24% +$602K 0.18% 103
2019
Q2
$2.54M Buy
137,446
+114,744
+505% +$2.12M 0.22% 99
2019
Q1
$420K Buy
22,702
+10,202
+82% +$180K 0.06% 540
2018
Q4
$207K Buy
+12,500
New +$218K 0.06% 588

Other funds holding TU

AlphaCrest Capital Management's TU Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Telus (TU) in Q4 2022, closing a stake of 28,315 shares — an estimated $562K sold.

AlphaCrest Capital Management first reported a position in TU in Q4 2018 and held it in 16 quarters. The position peaked at $3.52M in Q2 2022. 323 funds tracked by Wall St. Rank hold TU as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Telus position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 28,315 Telus shares in Q4 2022, an estimated $562K.
  • AlphaCrest Capital Management first reported a position in Telus in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Telus position peaked at $3.52M in Q2 2022.
  • 323 funds tracked by Wall St. Rank held Telus as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.